<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="fahn" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">fahn</book-part-id>
      <title-group>
        <title>Fatty Acid Hydroxylase-Associated Neurodegeneration</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kruer</surname>
            <given-names>Michael C</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Departments of Pediatrics, Neurology, &#x00026; Neuroscience<break/>Sanford Children&#x02019;s Research Center<break/>University of South Dakota Sanford School of Medicine<break/>Sioux Falls, South Dakota</aff>
          <email>michael.kruer@sanfordhealth.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gregory</surname>
            <given-names>Allison</given-names>
          </name>
          <degrees>MS</degrees>
          <aff>Department of Molecular and Medical Genetics<break/>Oregon Health &#x00026; Science University<break/>Portland, Oregon</aff>
          <email>gregorya@ohsu.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hayflick</surname>
            <given-names>Susan J</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Departments of Molecular and Medical Genetics, Pediatrics, and Neurology <break/>Oregon Health &#x00026; Science University<break/>Portland, Oregon</aff>
          <email>hayflick@ohsu.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2011-06-28" date-type="created">
          <day>28</day>
          <month>6</month>
          <year>2011</year>
        </date>
        <date iso-8601-date="2012-09-20" date-type="revised">
          <day>20</day>
          <month>9</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="fa" document-type="chapter">Fanconi Anemia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="feingold" document-type="chapter">Feingold Syndrome 1</related-object>
      <abstract id="fahn.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Fatty acid hydroxylase-associated neurodegeneration (FAHN) is characterized by central nervous system involvement including corticospinal tract involvement (spasticity), mixed movement disorder (ataxia/dystonia), eye findings (optic atrophy, oculomotor abnormalities) early in the disease course, and progressive intellectual impairment and seizures later in the disease course. FAHN is considered to be a subtype of neurodegeneration with brain iron accumulation (NBIA). To date, a total of 25 individuals from seven families of diverse ethnicity with FAHN have been described; much is yet to be learned about the clinical manifestations and natural history.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of FAHN may be suspected when characteristic neurologic findings are accompanied by supportive findings on brain MRI. <italic toggle="yes">FA2H</italic> is the only gene in which pathogenic variants are known to FAHN.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Symptomatic treatment is aimed primarily at the dystonia, which can be debilitating. Therapies used with varying success include the oral medications baclofen, anticholinergics, tizanidine, and dantrolene; focal injection of botulinum toxin targeting abnormal co-contraction of selected muscle groups; intrathecal baclofen; deep brain stimulation; and ablative pallidotomy or thalamotomy. Independence should be encouraged when possible through use of adaptive aids (e.g., walker or wheelchair for gait abnormalities; augmentative communication devices) and appropriate community resources (e.g., financial services, programs for the visually impaired, and special education).</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Attention to swallowing and diet to assure adequate nutrition and prevent aspiration; gastrostomy tube placement as needed.</p>
          <p><italic toggle="yes">Surveillance:</italic> Regular measurement of height and weight in children to assess nutritional status, ophthalmologic examination, and assessment of ambulation and environmental adaptations and swallowing, speech, and communication needs.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>FAHN is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. If the pathogenic variants have been identified in an affected family member, prenatal testing for at-risk pregnancies is possible through laboratories offering either prenatal testing for the gene of interest or custom testing.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="fahn.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="fahn.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_fahn.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Fatty Acid Hydroxylase-Associated Neurodegeneration: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_fahn.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Dysmyelinating leukodystrophy and spastic paraparesis with or without dystonia</p>
                    </list-item>
                    <list-item>
                      <p>Spastic paraplegia 35 (SPG35)</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="fahn.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="fahn.Diagnosis">
        <title>Diagnosis</title>
        <sec id="fahn.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of fatty acid hydroxylase-associated neurodegeneration (FAHN) may be suspected in individuals with in the first- or second-decade onset of the hallmark features: corticospinal tract involvement, movement disorder, and suggestive neuroimaging findings. See <xref ref-type="fig" rid="fahn.F1">Figure 1</xref>.</p>
          <sec id="fahn.Hallmark_Features">
            <title>Hallmark Features</title>
            <p>Note: Fewer than 30 individuals with FAHN have been reported; the phenotype is likely to expand as more cases are ascertained, and thus the designation of any phenotypic feature as &#x02018;hallmark&#x02019; may be premature.</p>
            <list list-type="bullet">
              <list-item>
                <p>Onset within the first or second decade of life</p>
              </list-item>
              <list-item>
                <p>Corticospinal tract involvement</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Spastic paraplegia or quadriplegia</p>
                  </list-item>
                  <list-item>
                    <p>Pyramidal tract signs (hypereflexia, clonus, Babinski sign, Hoffmann sign)</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Movement disorder including one or both of the following:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Dystonia</p>
                  </list-item>
                  <list-item>
                    <p>Ataxia</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Dysarthria</p>
              </list-item>
              <list-item>
                <p>Dysphagia</p>
              </list-item>
              <list-item>
                <p>Brain magnetic resonance imaging (MRI) findings typically including:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>T<sub>2</sub> hypointensity of the globus pallidus (may display blooming on T<sub>2</sub>*-weighted images). T<sub>2</sub> hypointensity coupled with an extrapyramidal movement disorder and intellectual decline is suggestive of a <related-object link-type="booklink" source-id="gene" document-id="nbia-ov" document-type="chapter">neurodegeneration with brain iron accumulation (NBIA) disorder</related-object> (see <xref ref-type="sec" rid="fahn.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
                  </list-item>
                  <list-item>
                    <p>T<sub>2</sub>-weighted images may demonstrate variable unilateral or bilateral symmetric white matter hyperintensity. These findings can affect both periventricular and subcortical white matter and may become confluent with time. The U-fibers and cerebellar white matter appear to be affected to a lesser degree.</p>
                  </list-item>
                  <list-item>
                    <p>Progressive atrophy of the cerebellar hemispheres, vermis, pons, medulla and spinal cord</p>
                  </list-item>
                  <list-item>
                    <p>Thinning of the corpus callosumNote: The 'eye of the tiger' sign, pathognomonic for <related-object link-type="booklink" source-id="gene" document-id="pkan" document-type="chapter">pantothenate kinase-associated neurodegeneration</related-object> (PKAN), another form of NBIA, is not seen in FAHN.</p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </sec>
          <sec id="fahn.Corroborative_Features">
            <title>Corroborative Features</title>
            <list list-type="bullet">
              <list-item>
                <p>Eye findings</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Optic atrophy manifest as progressive loss of visual acuity, sectoral visual field loss, and impaired color vision.</p>
                  </list-item>
                  <list-item>
                    <p>Other findings may include strabismus, lateral-beating nystagmus, and supranuclear gaze palsy</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Family history consistent with autosomal recessive inheritance, including parental consanguinity</p>
              </list-item>
            </list>
          </sec>
          <sec id="fahn.Pathologic_Diagnosis">
            <title>Pathologic Diagnosis</title>
            <p>Bone marrow biopsy, although not necessary for diagnosis, may demonstrate accumulation of granular histiocytes.</p>
            <p>Neuropathologic features for FAHN have not yet been reported.</p>
          </sec>
        </sec>
        <sec id="fahn.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">FA2H</italic> is the only gene in which pathogenic variants are known to cause fatty acid hydroxylase-associated neurodegeneration (FAHN).</p>
          <table-wrap id="fahn.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Fatty Acid Hydroxylase-Associated Neurodegeneration</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">FA2H</italic>
                  </td>
                  <td headers="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  <td headers="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon and whole-gene deletions/duplications&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_fahn.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="fahn.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="fahn" object-id="fahn.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="fahn.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="fahn.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="fahn.TF.1.3">
                <label>3. </label>
                <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
              </fn>
              <fn id="fahn.TF.1.4">
                <label>4. </label>
                <p>Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="fahn.TF.1.5">
                <label>5. </label>
                <p>Performed using primers spanning all seven exons and intron-exon boundaries of <italic toggle="yes">FA2H</italic> with comparison to reference sequence [<xref ref-type="bibr" rid="fahn.REF.kruer.2010.611">Kruer et al 2010</xref>]</p>
              </fn>
              <fn id="fahn.TF.1.6">
                <label>6. </label>
                <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="fahn.TF.1.7">
                <label>7. </label>
                <p>
                  <xref ref-type="bibr" rid="fahn.REF.pierson.2012.476">Pierson et al [2012]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Interpretation of test results.</bold> When only one pathogenic variant is identified in an individual with clinical and neuroimaging features of FAHN, a diagnosis of &#x02018;suspected FAHN&#x02019; is appropriate.</p>
        </sec>
        <sec id="fahn.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> The diagnosis of FAHN may be clinically suspected when the following are present:</p>
          <list list-type="bullet">
            <list-item>
              <p>A mixed movement disorder (ataxia/dystonia) and corticospinal tract findings</p>
            </list-item>
            <list-item>
              <p>Corroborative ophthalmologic features: optic atrophy, strabismus, nystagmus, and supranuclear gaze palsy</p>
            </list-item>
            <list-item>
              <p>Supportive findings on neuroimaging: T<sub>2</sub> hypointensity of the globus pallidus, T<sub>2</sub> subcortical white matter hyperintensity, and atrophy of the corpus callosum, brain stem, and cerebellum</p>
            </list-item>
          </list>
          <p>On the basis of this constellation of features, molecular genetic testing of <italic toggle="yes">FA2H</italic> should be considered first using sequence analysis. If no or only one pathogenic variant is identified, deletion/duplication analysis should be considered.</p>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="fahn.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="fahn.Clinical_Description">
          <title>Clinical Description</title>
          <p>Fatty acid hydroxylase-associated neurodegeneration (FAHN) is considered to represent a subtype of <related-object link-type="booklink" source-id="gene" document-id="nbia-ov" document-type="chapter">neurodegeneration with brain iron accumulation</related-object> (NBIA), a class of disorders that also includes <related-object link-type="booklink" source-id="gene" document-id="pkan" document-type="chapter">pantothenate kinase-associated neurodegeneration</related-object> (PKAN) and neuroaxonal dystrophy (NAD; see <related-object link-type="booklink" source-id="gene" document-id="inad" document-type="chapter">Infantile Neroaxonal Dystrophy</related-object>).</p>
          <p>The signs and symptoms of FAHN are largely confined to the central nervous system and include corticospinal tract involvement, movement disorder, and eye findings. To date, a total of 25 individuals from seven families of diverse ethnicity with FAHN have been described [<xref ref-type="bibr" rid="fahn.REF.dick.2008.248">Dick et al 2008</xref>, <xref ref-type="bibr" rid="fahn.REF.edvardson.2008.643">Edvardson et al 2008</xref>, <xref ref-type="bibr" rid="fahn.REF.dick.2010.e1251">Dick et al 2010</xref>, <xref ref-type="bibr" rid="fahn.REF.kruer.2010.611">Kruer et al 2010</xref>]; therefore, information on the extent of the phenotype and natural history are limited. (See <xref ref-type="table" rid="fahn.T.clinical_features_of_fahn_in_the">Table 2</xref>.)</p>
          <table-wrap id="fahn.T.clinical_features_of_fahn_in_the" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Clinical Features of FAHN in the 25 Individuals Reported to Date</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Heritage</th>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Affected Persons</th>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Age at Onset (yrs)</th>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Spasticity</th>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Ataxia</th>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Dystonia</th>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Optic Atrophy</th>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Seizures</th>
                  <th id="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Intellectual Decline</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Omani</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">7</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">6-11</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">7/7</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">ND</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">ND</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1">ND</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="top" align="left" rowspan="1" colspan="1">2/7</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="top" align="left" rowspan="1" colspan="1">3/7</td>
                </tr>
                <tr>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Arabic-1</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">4-6</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">3/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">2/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">3/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1">ND</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="top" align="left" rowspan="1" colspan="1">1/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="top" align="left" rowspan="1" colspan="1">3/3</td>
                </tr>
                <tr>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Arabic-2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">4-5</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">4/4</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">2/4</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">4/4</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1">ND</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="top" align="left" rowspan="1" colspan="1">1/4</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="top" align="left" rowspan="1" colspan="1">1/4</td>
                </tr>
                <tr>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Arabic-3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">4-6</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">2/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">0/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">0/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1">ND</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="top" align="left" rowspan="1" colspan="1">0/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="top" align="left" rowspan="1" colspan="1">ND</td>
                </tr>
                <tr>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pakistani</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">4</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">1/1</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">0/1</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">1/1</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1">1/1</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="top" align="left" rowspan="1" colspan="1">1/1</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="top" align="left" rowspan="1" colspan="1">1/1</td>
                </tr>
                <tr>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Italian</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">4-5</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">3/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">3/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">3/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1">3/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="top" align="left" rowspan="1" colspan="1">2/3</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="top" align="left" rowspan="1" colspan="1">3/3</td>
                </tr>
                <tr>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Albanian</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">3-4</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">2/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">2/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">2/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1">1/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="top" align="left" rowspan="1" colspan="1">1/2</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="top" align="left" rowspan="1" colspan="1">2/2</td>
                </tr>
                <tr>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">TOTAL</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">25 (22&#x000a0;<sup>1</sup>)</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">3-11</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">22/22</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1">9/15</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">13/15</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_7" valign="top" align="left" rowspan="1" colspan="1">5/6</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_8" valign="top" align="left" rowspan="1" colspan="1">8/22</td>
                  <td headers="hd_h_fahn.T.clinical_features_of_fahn_in_the_1_1_1_9" valign="top" align="left" rowspan="1" colspan="1">13/20</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>ND = not determined</p>
              </fn>
              <fn id="fahn.TF.2.1">
                <label>1. </label>
                <p>Only proband reported</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>The most frequent presenting finding is a subtle change in gait that may lead to increasingly frequent falls. This typically occurs in childhood or adolescence and may be the result of focal dystonia and/or corticospinal tract involvement.</p>
          <p>The degree of spasticity resulting from corticospinal tract involvement may vary among persons with FAHN. Individuals affected to a lesser degree may develop spastic paraparesis but retain the ability to walk, while individuals with more severe disease may demonstrate a spastic quadriplegic pattern of disability and lose their ability to ambulate, instead relying on a wheelchair.</p>
          <p>Dystonia may begin focally (e.g., affecting one foot) but typically spreads to assume a generalized pattern. The degree of dystonia seen in FAHN is generally milder than that in other forms of NBIA, such as PKAN, in which status dystonicus occurs.</p>
          <p>Ataxia typically begins in childhood or adolescence and may emerge along with dystonia and/or spasticity. The ataxia that occurs in FAHN may affect both axial and appendicular function and, along with both dystonia and spasticity, can markedly impair gait.</p>
          <p>Dysarthria may be prominent in FAHN. In some individuals, expressive speech can be impaired to the point of anarthria. Dysphagia, potentially necessitating gastrostomy tube placement, can also occur.</p>
          <p>Optic atrophy in FAHN may begin as a subtle loss of visual acuity in childhood, but may progress to the point of functional blindness. The oculomotor abnormalities seen in FAHN may impair functional vision as well.</p>
          <p>Seizures are not typically seen in the early stages of disease, but may occur later in the disease course. When present, seizures tend to be complex partial or generalized in nature but are typically infrequent and respond relatively well to anticonvulsants.</p>
          <p>Progressive intellectual impairment is reported in most persons with FAHN, although more detailed data on the cognitive phenotype and natural history are needed.</p>
          <p><bold>Leukodystrophy and hereditary spastic paraplegia 35 (HSP35)</bold> are two phenotypes previously identified as distinct disorders but now included in the phenotypic spectrum of FAHN:</p>
          <list list-type="bullet">
            <list-item>
              <p>Pathogenic variants in <italic toggle="yes">FA2H</italic> were first identified in a family with progressive dystonia and intellectual decline [<xref ref-type="bibr" rid="fahn.REF.edvardson.2008.643">Edvardson et al 2008</xref>]. Neuroimaging revealed widespread T<sub>2</sub> white matter hyperintensities consistent with a clinical diagnosis of leukodystrophy. Further review of neuroimaging revealed T<sub>2</sub> hypointensities in the globus pallidus [<xref ref-type="bibr" rid="fahn.REF.kruer.2010.611">Kruer et al 2010</xref>]. This phenotype likely represents a variant of FAHN.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="fahn.REF.dick.2008.248">Dick et al [2008]</xref> described spastic paraplegia and dystonia in a consanguineous Omani family. They mapped the disease-associated locus, which they designated SGP35, to 16q21-23. Subsequently, <xref ref-type="bibr" rid="fahn.REF.dick.2010.e1251">Dick et al [2010]</xref> identified pathogenic variants in <italic toggle="yes">FA2H</italic> in the index family as well as in an additional family from Pakistan. Affected individuals exhibited spastic paraplegia, dystonia, and optic atrophy, leading to the characterization of the SPG35-associated phenotype as a &#x02018;complicated&#x02019; form of HSP.</p>
            </list-item>
          </list>
          <p>Although FAHN is progressive, declines may be intermittent and punctuated by periods of relative clinical stability. However, lost skills are not usually regained. With disease progression, dystonia and spasticity compromise the ability to ambulate, leading to wheelchair dependence.</p>
          <p>Although premature death often occurs in the 20s or 30s secondary to a combination of nutrition-related immunodeficiency and respiratory compromise, life span is variable.</p>
          <p>Neuropathologic features for FAHN have not yet been reported.</p>
        </sec>
        <sec id="fahn.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No clear genotype-phenotype correlations have been observed for pathogenic variants in <italic toggle="yes">FA2H</italic>.</p>
        </sec>
        <sec id="fahn.Nomenclature">
          <title>Nomenclature</title>
          <p>FAHN was called &#x02018;hereditary spastic paraplegia 35 (HSP35)&#x02019; by <xref ref-type="bibr" rid="fahn.REF.dick.2008.248">Dick et al [2008]</xref>. More recently <xref ref-type="bibr" rid="fahn.REF.dick.2010.e1251">Dick et al [2010]</xref> identified <italic toggle="yes">FA2H</italic> pathogenic variants in two families with HSP35 (see <xref ref-type="sec" rid="fahn.Clinical_Description">Clinical Description</xref>, <bold>Leukodystrophy and hereditary spastic paraplegia 35</bold>).</p>
        </sec>
        <sec id="fahn.Prevalence">
          <title>Prevalence</title>
          <p>No reliable prevalence data on this rare disorder have been collected. However, the prevalence is estimated to be less than one in 1,000,000.</p>
        </sec>
      </sec>
      <sec id="fahn.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Two phenotypes previously identified as distinct disorders are now included in the phenotypic spectrum of FAHN (see <xref ref-type="sec" rid="fahn.Clinical_Description">Clinical Description</xref>, <bold>Leukodystrophy and hereditary spastic paraplegia 35</bold>).</p>
        <p>No other phenotypes are known to be associated with pathogenic variants in <italic toggle="yes">FA2H</italic>.</p>
      </sec>
      <sec id="fahn.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Clinical suspicion that an individual may have a form of <related-object link-type="booklink" source-id="gene" document-id="nbia-ov" document-type="chapter">neurodegeneration with brain iron accumulation</related-object> (NBIA) typically arises in the context of a progressive extrapyramidal movement disorder, intellectual decline, and neuroimaging that demonstrates iron deposition in the globus pallidus.</p>
        <p>Fatty acid hydroxylase-associated neurodegeneration (FAHN) is a neurodegenerative disorder that clinically shows overlap with other early-onset neurodegenerative disorders. Disorders that may exhibit clinical and neuroimaging features similar to those seen in FAHN include the following.</p>
        <p>
          <bold>Other forms of NBIA</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>Spinocerebellar ataxias (SCAs) (see <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">Hereditary Ataxia Overvew</related-object>)</p>
          </list-item>
          <list-item>
            <p>Complicated hereditary spastic paraplegias (HSPs) (see <related-object link-type="booklink" source-id="gene" document-id="hsp" document-type="chapter">Hereditary Spastic Paraplegia Overview</related-object>)</p>
          </list-item>
          <list-item>
            <p>Monogenic Parkinson disease and parkinsonism-dystonias with onset at a young age, including <related-object link-type="booklink" source-id="gene" document-id="jpd" document-type="chapter">Parkin type of Juvenile Parkinson disease</related-object>, and pallido-pyramidal syndromes associated with pathogenic variants in <italic toggle="yes">FBXO7, ATP13A2</italic>, <italic toggle="yes">PLA2G6</italic>, or <italic toggle="yes">SPG11</italic> [<xref ref-type="bibr" rid="fahn.REF.pais_nruiz.2010.1791">Paisan-Ruiz et al 2010</xref>] (see also <related-object link-type="booklink" source-id="gene" document-id="parkinson-overview" document-type="chapter">Parkinson Disease Overview</related-object>)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="mcleod" document-type="chapter">McLeod syndrome</related-object> and other neuroacanthocytosis syndromes</p>
          </list-item>
          <list-item>
            <p>Dopa-responsive dystonia (see <related-object link-type="booklink" source-id="gene" document-id="drd" document-type="chapter">GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia</related-object> and <related-object link-type="booklink" source-id="gene" document-id="thdrd" document-type="chapter">Tyrosine Hydroxylase Deficiency</related-object>)</p>
          </list-item>
          <list-item>
            <p>Leukodystrophies. The leukodystrophy associated with FAHN has been incompletely characterized as insufficient serial neuroimaging is available to determine if a characteristic pattern of white matter injury occurs. It would be reasonable to consider in the differential diagnosis those disorders that affect:</p>
            <list list-type="bullet">
              <list-item>
                <p>White matter diffusely (e.g., <related-object link-type="booklink" source-id="gene" document-id="canavan" document-type="chapter">Canavan disease</related-object>)</p>
              </list-item>
              <list-item>
                <p>Anterior white matter preferentially (e.g., metachromatic leukodystrophy (see <related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter">Arylsulfatase A Deficiency</related-object>), <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object> (X-ALD), or <related-object link-type="booklink" source-id="gene" document-id="hdls" document-type="chapter">hereditary diffuse leukoencephalopathy with spheroids</related-object></p>
              </list-item>
              <list-item>
                <p>Posterior white matter (e.g., <related-object link-type="booklink" source-id="gene" document-id="x-ald" document-type="chapter">X-linked adrenoleukodystrophy</related-object>, <related-object link-type="booklink" source-id="gene" document-id="krabbe" document-type="chapter">Krabbe disease</related-object>).</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Several disorders may feature symmetric T<sub>2</sub>-weighted <bold>hyperintense (&#x02018;MRI bright&#x02019;)</bold> lesions in the globus pallidus, suggesting metabolic compromise. Examples include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="bgd-biotin" document-type="chapter">Biotin-responsive dystonia</related-object> (caused by pathogenic variants in <italic toggle="yes">SLC19A3</italic>) [<xref ref-type="bibr" rid="fahn.REF.zeng.2005.16">Zeng et al 2005</xref>]</p>
          </list-item>
          <list-item>
            <p>Variants of Leigh disease (see <related-object link-type="booklink" source-id="gene" document-id="narp" document-type="chapter">Mitochondrial DNA-Associated Leigh Syndrome and NARP</related-object> [<xref ref-type="bibr" rid="fahn.REF.quintana.2009">Quintana et al 2009</xref>]</p>
          </list-item>
          <list-item>
            <p>Glutaric aciduria [<xref ref-type="bibr" rid="fahn.REF.harting.2009.1764">Harting et al 2009</xref>]</p>
          </list-item>
          <list-item>
            <p>Postinfectious/autoimmune striatal necrosis [<xref ref-type="bibr" rid="fahn.REF.dale.2002.485">Dale et al 2002</xref>]</p>
          </list-item>
        </list>
        <p>Conversely, although a small area of central hyperintensity within the otherwise hypointense globi pallidi can be seen as the &#x02018;eye&#x02019; in the &#x02018;eye of the tiger&#x02019; sign observed in <related-object link-type="booklink" source-id="gene" document-id="pkan" document-type="chapter">pantothenate kinase-associated neurodegeneration</related-object> (PKAN), other forms of NBIA, including FAHN, characteristically feature uniformly symmetric T<sub>2</sub> hypointense (&#x02018;MRI dark&#x02019;) globi pallidi (see <related-object link-type="booklink" source-id="gene" document-id="pkan" document-type="chapter">PKAN</related-object>, <xref ref-type="fig" rid="fahn.F1">Figure 1</xref>).</p>
        <p>The differential diagnosis of a neurodegenerative disorder associated with T<sub>2</sub> hypointensity of the globus pallidus is largely limited to other mineral deposition disorders.</p>
        <list list-type="bullet">
          <list-item>
            <p>Striatonigral calcinosis likely represents a heterogeneous patient group that share a propensity to deposit calcium in the basal ganglia. Features of this disease may be similar to those of NBIA. However, the two disorders are readily distinguished by CT scan, on which calcium appears hyperdense, while iron appears isodense to the surrounding parenchyma.</p>
          </list-item>
          <list-item>
            <p>An as-yet-unnamed hereditary metabolic disorder that results in similar findings has been described [<xref ref-type="bibr" rid="fahn.REF.tuschl.2008.151">Tuschl et al 2008</xref>].</p>
          </list-item>
        </list>
        <p>Miners and persons with liver failure are at risk for brain manganese deposition associated with T<sub>1</sub> hyperintense lesions of the globus pallidus which, on T<sub>2</sub>-weighted sequences, are typically indistinguishable from surrounding brain tissue.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="wilson" document-type="chapter">Wilson disease</related-object>, a disorder of copper metabolism that can present with hepatic, neurologic, or psychiatric disturbances, or a combination of these presenting between ages three years and more than 50 years, may feature mixed T<sub>2</sub> hyperintensity and hypointensity on MRI. Neurologic findings include movement disorders (tremors, dystonia, chorea, poor coordination, loss of fine-motor control,) or rigidity/parkinsonism (mask-like facies, gait disturbance, pseudobulbar involvement). Diagnosis depends on the detection of low serum copper and ceruloplasmin concentrations; increased urinary copper excretion; and molecular genetic testing of <italic toggle="yes">ATP7B</italic>.</p>
        <p>Other disorders to consider:</p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="ncl" document-type="chapter">Neuronal ceroid lipofuscinosis</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Juvenile-onset <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object></p>
          </list-item>
          <list-item>
            <p>Lysosomal storage disorders including <related-object link-type="booklink" source-id="gene" document-id="npc" document-type="chapter">Niemann-Pick type C</related-object></p>
          </list-item>
          <list-item>
            <p>Peroxisomal biogenesis disorders (See <related-object link-type="booklink" source-id="gene" document-id="pbd" document-type="chapter">Peroxisomal Biogenesis Disorders, Zellweger Type</related-object>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="creatine" document-type="chapter">Disorders of creatine metabolism</related-object>
            </p>
          </list-item>
        </list>
      </sec>
      <sec id="fahn.Management">
        <title>Management</title>
        <sec id="fahn.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with fatty acid hydroxylase-associated neurodegeneration (FAHN), the following evaluations may be useful:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic examination for dystonia, ataxia, and spasticity, including formal evaluation of ambulation, speech, and feeding</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic assessment for evidence of optic atrophy or eye movement abnormalities</p>
            </list-item>
            <list-item>
              <p>Screening developmental assessment, with referral for more formal testing if delay is indicated</p>
            </list-item>
            <list-item>
              <p>Assessment for physical therapy, occupational therapy, and/or speech therapy and appropriate assistive devices</p>
            </list-item>
          </list>
        </sec>
        <sec id="fahn.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Pharmacologic and surgical interventions have focused on palliation of symptoms.</p>
          <p>Weighted gloves can sometimes be used to assist with dysmetria.</p>
          <p>Symptomatic treatment is aimed primarily at the dystonia, which can be debilitating. Therapies to manage dystonia in affected individuals that have been used with varying success include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Oral trihexyphenidyl, baclofen, tizanidine, benzodiazepines, and/or dantrolene</p>
            </list-item>
            <list-item>
              <p>Intramuscular botulinum toxin targeting abnormal co-contraction of selected muscle groups</p>
            </list-item>
            <list-item>
              <p>Ablative pallidotomy or thalamotomy. Dystonia may return despite this aggressive measure [<xref ref-type="bibr" rid="fahn.REF.justesen.1999.551">Justesen et al 1999</xref>]. (For discussion of deep brain stimulation [DBS] see <xref ref-type="sec" rid="fahn.Therapies_Under_Investigation">Therapies Under Investigation</xref>.)</p>
            </list-item>
          </list>
          <p>It is important to help affected individuals to maintain independence whenever possible.</p>
          <list list-type="bullet">
            <list-item>
              <p>Affected individuals should be referred to appropriate community resources for financial services, services for the visually impaired (if optic atrophy is present), and special education.</p>
            </list-item>
            <list-item>
              <p>As needed, individuals should be referred for adaptive aids such as a walker or wheelchair for gait abnormalities and augmentative communication devices.</p>
            </list-item>
          </list>
        </sec>
        <sec id="fahn.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Swallowing evaluation and regular dietary assessments are indicated to assure adequate nutrition and prevent aspiration. Once the individual can no longer maintain an adequate diet orally, gastrostomy tube placement is indicated.</p>
        </sec>
        <sec id="fahn.Surveillance">
          <title>Surveillance</title>
          <p>The following should be performed on a regular basis:</p>
          <list list-type="bullet">
            <list-item>
              <p>Monitoring of height and weight using appropriate growth curves to screen children for worsening nutritional status</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic assessment. Fundus photography may be helpful in characterizing changes in the optic nerve over time.</p>
            </list-item>
            <list-item>
              <p>Assessment of ambulation, speech, and swallowing</p>
            </list-item>
            <list-item>
              <p>Regular review of communication needs and environmental adaptations</p>
            </list-item>
          </list>
        </sec>
        <sec id="fahn.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="fahn.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="fahn.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><bold>Deep brain stimulation (DBS).</bold> To the authors&#x02019; knowledge, DBS has not yet been employed in the treatment of dystonia secondary to FAHN. Ongoing studies in the use of DBS for the management of other forms of NBIA suggest that it does provide benefit to a subset of affected individuals [<xref ref-type="bibr" rid="fahn.REF.timmermann.2010.701">Timmermann et al 2010</xref>]. Future studies will be necessary to determine whether DBS may be similarly useful for dystonia in FAHN.</p>
          <p><bold>Intrathecal baclofen pump.</bold> The implantable intrathecal baclofen pump has shown efficacy in ameliorating dystonia in some forms of NBIA. The intraventricular baclofen pump has been used successfully in at least one person with NBIA among a cohort of individuals with refractory dystonia [<xref ref-type="bibr" rid="fahn.REF.albright.2009.11">Albright &#x00026; Ferson 2009</xref>]. Additional experience is necessary to better define the optimal mode of drug delivery and risk/benefit ratio.</p>
          <p><bold>Iron chelation.</bold> Interest in iron chelation has reemerged as trials using deferiprone have been published in other disorders of brain iron accumulation, including <related-object link-type="booklink" source-id="gene" document-id="friedreich" document-type="chapter">Friedreich ataxia</related-object> [<xref ref-type="bibr" rid="fahn.REF.boddaert.2007.401">Boddaert et al 2007</xref>] and superficial siderosis [<xref ref-type="bibr" rid="fahn.REF.levy.2011.e1">Levy &#x00026; Llinas 2011</xref>]. Deferiprone can cross the blood-brain barrier and remove intracellular iron.</p>
          <list list-type="bullet">
            <list-item>
              <p>A single case report suggests regression of symptoms in an adult with NBIA of unknown cause [<xref ref-type="bibr" rid="fahn.REF.forni.2008.904">Forni et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>A recently completed phase II deferiprone trial in Italy in persons with PKAN demonstrated after six months of treatment decreased T<sub>2</sub> hypointensity but no detectable change in clinical symptom severity [<xref ref-type="bibr" rid="fahn.REF.zorzi.2011.1756">Zorzi et al 2011</xref>]. No serious treatment-related adverse events occurred.</p>
            </list-item>
          </list>
          <p>Long-term clinical trials of deferiprone in specific forms of NBIA will be necessary to further assess safety and efficacy.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="fahn.Other">
          <title>Other</title>
          <p>Riluzole, recently recommended for cerebellar ataxia [<xref ref-type="bibr" rid="fahn.REF.ristori.2010.839">Ristori et al 2010</xref>], has not to the authors&#x02019; knowledge undergone a therapeutic trial in FAHN.</p>
        </sec>
      </sec>
      <sec id="fahn.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="fahn.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Fatty acid hydroxylase-associated neurodegeneration (FAHN) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="fahn.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one mutated allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The offspring of an individual with FAHN are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">FA2H</italic>.</p>
            </list-item>
            <list-item>
              <p>Unless an individual with FAHN has children with an affected individual or a carrier, his/her offspring will be obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">FA2H.</italic></p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="fahn.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>If the pathogenic variants in the family have been identified, carrier testing for at-risk family members is possible through laboratories offering either testing for the gene of interest or custom testing.</p>
        </sec>
        <sec id="fahn.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="fahn.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">FA2H</italic> pathogenic variants have been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for FAHN are possible options.</p>
        </sec>
      </sec>
      <sec id="fahn.Resources">
        <title>Resources</title>
      </sec>
      <sec id="fahn.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="fahn.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Human <italic toggle="yes">FA2H</italic> encodes the fatty acid 2-hydroxylase, an enzyme that alpha-hydroxylates nascent fatty acids that are subsequently incorporated into several diverse lipid species. Pathogenic variants in <italic toggle="yes">FA2H</italic> are believed to lead to fatty acid hydroxylase-associated neurodegeneration (FAHN) through a loss-of-function mechanism. This is supported by the identification of variants that lead to premature truncation of the protein [<xref ref-type="bibr" rid="fahn.REF.kruer.2010.611">Kruer et al 2010</xref>], as well as in vitro evidence of decreased &#x003b1;-hydroxylation activity [<xref ref-type="bibr" rid="fahn.REF.dick.2010.e1251">Dick et al 2010</xref>] and decreased protein abundance [<xref ref-type="bibr" rid="fahn.REF.kruer.2010.611">Kruer et al 2010</xref>] secondary to pathogenic variants associated with clinical FAHN.</p>
          <p>In the peripheral nervous system, there is evidence that a second fatty acid-hydroxylating enzyme (perhaps phytanoyl coA 2-hydroxylase) may compensate for loss of FA2H activity [<xref ref-type="bibr" rid="fahn.REF.edvardson.2008.643">Edvardson et al 2008</xref>]. However, in the central nervous system, this redundancy does not seem to exist. A decrease in 2-OH fatty acids may lead to abnormal white matter, as 2-OH sphingomyelin is an important myelin constituent [<xref ref-type="bibr" rid="fahn.REF.eckhardt.2005.245">Eckhardt et al 2005</xref>]. Deficiency of 2-OH fatty acids may also lead to an abnormal increase in membrane fluidity [<xref ref-type="bibr" rid="fahn.REF.guo.2010.25438">Guo et al 2010</xref>], with implications for the regulation of autophagy via the endosomal-lysosomal system. An important cell-cycle signaling role for <italic toggle="yes">FA2H</italic> has also been shown [<xref ref-type="bibr" rid="fahn.REF.alderson.2009.1203">Alderson &#x00026; Hama 2009</xref>]. However, further investigation is needed to better characterize the mechanism(s) by which loss of functional FA2H may lead to FAHN.</p>
          <p><bold>Gene structure.</bold> The reference sequence <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_024306.4">NM_024306.4</ext-link> has seven exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="fahn" object-id="fahn.molgen.TA">Table A,</related-object>
<bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> No common sequence variants have been identified to date in persons with FAHN; all have been &#x02018;private&#x02019; variants.</p>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">FA2H</italic> encodes a 43-kd protein of 372 amino acid residues that is a functional fatty acid hydroxylase [<xref ref-type="bibr" rid="fahn.REF.alderson.2004.48562">Alderson et al 2004</xref>]. This protein is known to localize to the endoplasmic reticulum and to require iron as a cofactor. Hydroxy fatty acids have important structural and signal transduction roles.</p>
          <p><bold>Abnormal gene product.</bold> Pathogenic variants can generally be categorized into null or missense alleles. Pathogenic missense variants in <italic toggle="yes">FA2H</italic> have been detected, leading to decreased protein abundance or enzyme activity. Null alleles have been detected as well.</p>
        </sec>
      </sec>
      <sec id="fahn.References">
        <title>References</title>
        <sec id="fahn.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="fahn.Literature_Cited.reflist0">
            <ref id="fahn.REF.albright.2009.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Albright</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferson</surname>
                    <given-names>SS</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Intraventricular baclofen for dystonia: techniques and outcomes. Clinical article.</article-title>
                <source>J Neurosurg Pediatr.</source>
                <volume>3</volume>
                <fpage>11</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19119897</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.alderson.2004.48562">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alderson</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rembiesa</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walla</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bielawska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bielawski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hama</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The human FA2H gene encodes a fatty acid 2-hydroxylase.</article-title>
                <source>J Biol Chem.</source>
                <volume>279</volume>
                <fpage>48562</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15337768</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.alderson.2009.1203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alderson</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hama</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Fatty acid 2-hydroxylase regulates cAMP-induced cell cycle exit in D6P2T schwannoma cells.</article-title>
                <source>J Lipid Res.</source>
                <volume>50</volume>
                <fpage>1203</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19171550</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.boddaert.2007.401">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boddaert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Quan Sang</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;tig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy-Willig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunelle</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thalabard</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabantchik</surname>
                    <given-names>ZI</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Selective iron chelation in Friedreich ataxia: biologic and clinical implications.</article-title>
                <source>Blood.</source>
                <volume>110</volume>
                <fpage>401</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17379741</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.dale.2002.485">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dale</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Church</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benton</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Surtees</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lees</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giovannoni</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neville</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Post-streptococcal autoimmune dystonia with isolated bilateral striatal necrosis.</article-title>
                <source>Dev Med Child Neurol.</source>
                <volume>44</volume>
                <fpage>485</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12162386</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.dick.2008.248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dick</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Mjeni</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baskir</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koul</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simpson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patton</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raeburn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crosby</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A novel locus for an autosomal recessive hereditary spastic paraplegia (SPG35) maps to 16q21-q23.</article-title>
                <source>Neurology.</source>
                <volume>71</volume>
                <fpage>248</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">18463364</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.dick.2010.e1251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dick</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eckhardt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pais&#x000e1;n-Ruiz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alshehhi</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proukakis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sibtain</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maier</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharifi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patton</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bashir</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koul</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raeburn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gieselmann</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crosby</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35).</article-title>
                <source>Hum Mutat.</source>
                <volume>31</volume>
                <fpage>E1251</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">20104589</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.eckhardt.2005.245">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eckhardt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaghootfam</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fewou</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Z&#x000f6;ller</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gieselmann</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A mammalian fatty acid hydroxylase responsible for the formation of alpha-hydroxylated galactosylceramide in myelin.</article-title>
                <source>Biochem J.</source>
                <volume>388</volume>
                <fpage>245</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">15658937</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.edvardson.2008.643">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Edvardson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hama</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaag</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomori</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berger</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soffer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taustein</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>83</volume>
                <fpage>643</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19068277</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.forni.2008.904">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Forni</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremonesi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abbruzzese</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parodi</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchese</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation.</article-title>
                <source>Mov Disord.</source>
                <volume>23</volume>
                <fpage>904</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18383118</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.guo.2010.25438">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pryse</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okunade</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Su</surname>
                    <given-names>X</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Fatty acid 2-hydroxylase mediates diffusional mobility of Raft-associated lipids, GLUT4 level, and lipogenesis in 3T3-L1 adipocytes.</article-title>
                <source>J Biol Chem.</source>
                <volume>285</volume>
                <fpage>25438</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">20519515</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.harting.2009.1764">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harting</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumaier-Probst</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seitz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maier</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baric</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Troncoso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;hlhausen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boy</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garbade</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;lker</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Dynamic changes of striatal and extrastriatal abnormalities in glutaric aciduria type I.</article-title>
                <source>Brain.</source>
                <volume>132</volume>
                <fpage>1764</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">19433437</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.justesen.1999.551">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Justesen</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penn</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kroin</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egel</surname>
                    <given-names>RT</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Stereotactic pallidotomy in a child with Hallervorden-Spatz disease. Case report.</article-title>
                <source>J Neurosurg.</source>
                <volume>90</volume>
                <fpage>551</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10067928</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.kruer.2010.611">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kruer</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pais&#x000e1;n-Ruiz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boddaert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoon</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hama</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malandrini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woltjer</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gobin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polster</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmeri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edvardson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA).</article-title>
                <source>Ann Neurol.</source>
                <volume>68</volume>
                <fpage>611</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20853438</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.levy.2011.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Llinas</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis.</article-title>
                <source>AJNR Am J Neuroradiol.</source>
                <volume>32</volume>
                <fpage>E1</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">21051507</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.pais_nruiz.2010.1791">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pais&#x000e1;n-Ruiz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guevara</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federoff</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanagasi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sina</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elahi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwingenschuh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bajaj</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singleton</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hardy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhatia</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lees</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.</article-title>
                <source>Mov Disord.</source>
                <volume>25</volume>
                <fpage>1791</fpage>
                <lpage>800</lpage>
                <pub-id pub-id-type="pmid">20669327</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.pierson.2012.476">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pierson</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simeonov</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sincan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markello</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golas</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuentes-Fajardo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hansen</surname>
                    <given-names>NF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherukuri</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cruz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mullikin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blackstone</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tifft</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boerkoel</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <collab>NISC Comparative Sequencing Program</collab>
                </person-group>
                <article-title>Exome sequencing and SNP analysis detect novel compound heterozygosity in fatty acid hydroxylase-associated neurodegeneration.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <volume>20</volume>
                <fpage>476</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22146942</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.quintana.2009">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quintana</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayr</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a Silva</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Font</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tortoledo</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moliner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozaez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lluch</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricoy</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briones</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>PDH E(1)beta deficiency with novel mutations in two patients with Leigh syndrome.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2009</year>
                <comment>Epub ahead of print</comment>
              </element-citation>
            </ref>
            <ref id="fahn.REF.ristori.2010.839">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ristori</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visconti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cannoni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spadaro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frontali</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pontieri</surname>
                    <given-names>FE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanacore</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvetti</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial.</article-title>
                <source>Neurology.</source>
                <volume>74</volume>
                <fpage>839</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">20211908</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.timmermann.2010.701">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Timmermann</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pauls</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jech</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurlemann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gill</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haenggeli</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogarth</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leenders</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Limousin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malanga</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostrem</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Revilla</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santens</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schnitzler</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tisch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valldeoriola</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vesper</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Volkmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woitalla</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peker</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation.</article-title>
                <source>Brain.</source>
                <volume>133</volume>
                <fpage>701</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">20207700</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.tuschl.2008.151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tuschl</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parsons</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fowler</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bitner-Glindzicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia-A new metabolic disorder.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>31</volume>
                <fpage>151</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">18392750</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.zeng.2005.16">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zeng</surname>
                    <given-names>WQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Yamani</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acierno</surname>
                    <given-names>JS</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Slaugenhaupt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillis</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozand</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gusella</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>77</volume>
                <fpage>16</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">15871139</pub-id>
              </element-citation>
            </ref>
            <ref id="fahn.REF.zorzi.2011.1756">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zorzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zibordi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiapparini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piga</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garavaglia</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aquino</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savoiardo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solari</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nardocci</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial.</article-title>
                <source>Mov Disord.</source>
                <volume>26</volume>
                <fpage>1756</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21557313</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="fahn.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="fahn.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>20 September 2012 (cd) Revision: deletion/duplication analysis available clinically</p>
            </list-item>
            <list-item>
              <p>28 June 2011 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>3 January 2011 (mk) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="fahn.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Neuroimaging features of FAHN (A) vs PKAN (B)The two forms of NBIA share T<sub>2</sub>/GRE hypointensity. Distinguishing features include diffuse cerebral atrophy (seen in FAHN) and central globus pallidus T<sub>2</sub> hyperintensity (seen in PKAN), producing the characteristic &#x02018;eye of the tiger&#x02019; sign.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fahn-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
